IL Therapeutics Inc. was previously owned by Western Life Sciences Venture Fund LP
("Western Life Sciences") and in 2006 its shares were purchased by Pacgen Biopharmaceuticals Corporation ("Pacgen").[1][2]
History
Saskatchewan Research Council operates a bioprocessing laboratory which facilitated biomedical research. IL Therapeutics was developed from research first begun at the Western College of Veterinary Medicine.
Pharmaceuticals
Currently IL Therapeutics is working on a drug candidate, IL-8(3-73)K11R/G31P ("PAC-G31P") for relief of Acute Respiratory Distress Syndrome (ARDS).[1] The Saskatchewan Research council, SRC also assisted with the funding of this project through the Agriculture Development Fund - SRC Industry Venture Fund.[3] With the successful progression of G31P, the University of Saskatchewan Industry Liaison Office (ILO) decided to commercialize a commercialize this new drug treatment.[4] This research has been sponsored by a $3 million boost from the Western Life Sciences Venture Fund (WLS)[5]
^Saskatchewan Research Council 2005-2006 Annual Report. Sustainable Science Solutions. pp. 7–8. Archived from the original on July 6, 2011. Retrieved August 11, 2018.{{cite book}}: CS1 maint: numeric names: authors list (link)